Solascure, Ltd.
SolasCure is dedicated to transforming chronic wound care through innovative therapeutic solutions. The company is at the forefront of developing Aurase Wound Gel, a breakthrough enzymatic debrider designed to return chronic wounds to healing. SolasCure aims to shift the paradigm in wound care by providing high-impact, safe, and effective treatments that address the underlying causes of wounds rather than just managing symptoms. With a strong focus on research and development, SolasCure is committed to improving the health and wellbeing of patients worldwide.
Industries
Nr. of Employees
small (1-50)
Solascure, Ltd.
Cambridge, Cambridgeshire, United Kingdom, Europe
Products
Aurase Wound Gel
A topical hydrogel formulation delivering a recombinant protease-based enzyme designed to enzymatically debride non-viable wound tissue, disrupt biofilm and support wound-bed preparation across clinic, hospital and community settings.
Aurase Wound Gel
A topical hydrogel formulation delivering a recombinant protease-based enzyme designed to enzymatically debride non-viable wound tissue, disrupt biofilm and support wound-bed preparation across clinic, hospital and community settings.
Services
Non-clinical research collaborations
Collaborative non-clinical projects to evaluate antimicrobial, anti-biofilm and bioburden reduction properties of topical enzymatic formulations in vitro and in vivo (example partnership with a military surgical research institute).
Clinical trial sponsorship and execution
Sponsorship and execution of human clinical studies including Phase IIa safety and proof-of-concept trials with endpoint reporting suitable for peer-reviewed publication.
Non-clinical research collaborations
Collaborative non-clinical projects to evaluate antimicrobial, anti-biofilm and bioburden reduction properties of topical enzymatic formulations in vitro and in vivo (example partnership with a military surgical research institute).
Clinical trial sponsorship and execution
Sponsorship and execution of human clinical studies including Phase IIa safety and proof-of-concept trials with endpoint reporting suitable for peer-reviewed publication.
Expertise Areas
- Clinical trial management and execution
- Enzymatic therapeutic development for wound care
- Recombinant protein expression and production
- Hydrogel biomaterial formulation for topical delivery
Key Technologies
- Recombinant protein expression
- Protease-based enzymatic debridement
- Hydrogel delivery systems
- pH-responsive enzyme mechanisms